Compare AbbVie Inc (ABBV) vs Intel Corp (INTC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Intel Corp — how do they compare? AbbVie Inc trades at $253.62 (market cap $449.91B), while Intel Corp trades at $107.33 (market cap $554.82B). The key difference: Intel Corp is the larger of the two by market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | INTC | |
|---|---|---|
Market Cap | $449.91B | $554.82B |
Sector | Health | Technology |
52-Week High | $261.07 | $140.94 |
52-Week Low | $184.85 | $19.31 |
Enterprise Value | $513.38B | $567.06B |
Dividend Yield | 2.72% | 2.24% |
Volume | — | 43,552,012 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Intel (INTC) trades at $110.39, down 8.28% amid a sector-wide chip selloff triggered by Samsung's earnings reaction. Despite beating EPS estimates for three consecutive quarters, the stock shows weak profitability with a negative net income margin and ROE. Technical indicators are neutral, with support at $114 and resistance at $124. Cash flow improved in 2025, but revenue remains flat year-over-year, highlighting growth challenges.
The outlook is mixed: analyst consensus is a 'Hold' with a $97.74 price target below current levels, reflecting skepticism about near-term execution. Risks include intense competition and cyclical semiconductor demand, but potential upside exists if foundry partnerships and AI-driven CPU demand materialize as projected by bullish analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →
